Evidence map›Paper›PMID 40463065›Full record

ArticlebioRxiv : the preprint server for biology2025

A functionally validated TCR-pMHC database for TCR specificity model development.

Marius Messemaker, Bjørn P Y Kwee, Živa Moravec, Daniel Álvarez-Salmoral, Jos Urbanus, Sam de Paauw, Jeroen Geerligs, Rhianne Voogd, Ben Morris, Aurélie Guislain and 10 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Marius MessemakerDivision of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0002-7179-0594
Bjørn P Y KweeDivision of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0001-6733-5022
Živa MoravecDivision of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0009-0001-4351-5317
Daniel Álvarez-SalmoralOncode Institute, Utrecht, The Netherlands.ORCID 0009-0009-1407-3909
Jos UrbanusDivision of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0003-3074-8477
Sam de PaauwDivision of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0009-0004-0558-9181
Jeroen GeerligsDivision of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0001-9263-610X
Rhianne VoogdDivision of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Ben MorrisDivision of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Aurélie GuislainDivision of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Maike MußmannDivision of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Yaël WinklerDivision of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0009-0001-8257-3798
Maxime SteinmetzDivision of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Matyas IrasDivision of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Eric MarcusDivision of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0002-3375-6248
Jonas TeuwenDivision of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0002-1825-1428
Anastassis PerrakisOncode Institute, Utrecht, The Netherlands.ORCID 0000-0002-1151-6227
Roderick L BeijersbergenDivision of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0003-0116-4130
Wouter ScheperDivision of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0003-1555-587X
Ton N SchumacherDivision of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0003-0517-8804

Funding

MATCHMAKERSOT2CA297206 · NCI · NETHERLANDS CANCER INSTITUTE · PI SCHUMACHER, TON · 2024 to 2024
$168k
NCI NIH HHS OT2 CA297206
6 · The paper itself

Abstract

Accurate prediction of TCR specificity forms a holy grail in immunology and large language models and computational structure predictions provide a path to achieve this. Importantly, current TCR-pMHC prediction models have been trained and evaluated using historical data of unknown quality. Here, we develop and utilize a high-throughput synthetic platform for TCR assembly and evaluation to assess a large fraction of VDJdb-deposited TCR-pMHC entries using a standardized readout of TCR function. Strikingly, this analysis demonstrates that claimed TCR reactivity is only confirmed for 50% of evaluated entries. Intriguingly, the use of TCRbridge to analyze AlphaFold3 confidence metrics reveals a substantial performance in distinguishing functionally validating and non-validating TCRs even though AlphaFold3 was not trained on this task, demonstrating the utility of the validated VDJdb (TCRvdb) database that we generated. We provide TCRvdb as a resource to the community to support training and evaluation of improved predictive TCR specificity models.

Indexed as

functional genetic screeningmajor histocompatibility antigenpeptidepredictive modelsT cell receptor

Identifiers

PMID40463065
PMCPMC12132471

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.